A panel of FDA advisers voted in favor of approving Daiichi Sankyo’s irregular heartbeat treatment edoxaban, heralding its ability to break up blood clots and improving the company’s odds of finally launching the drug in the U.S.

…read more

Source: Daiichi Sankyo’s new a-fib drug heads toward FDA approval and a crowded market


0 No comments